APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its fireside chat at an upcoming investor conference hosted by Bank of America.

Updated Conference Details

  • Bank of America Global Healthcare Conference: Fireside chat on Friday, September 16, 2022 at 9:55 a.m. BST / 4:55 a.m. ET.

The conference events will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s . Replays of the webcasts will be available for 30 days following the event.

About Apellis 

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit  or follow us on  and .

Investor Contact:

Meredith Kaya



617.599.8178

 



EN
12/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

 PRESS RELEASE

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT...

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent results across adolescent and adult patients with C3G and primary IC-MPGN, including patients with C3G recurring after transplantEMPAVELI is the first FDA-approved treatment for C3G and primary IC-MPGN patients 12 and older WALTHAM, Mass., Dec. 03, 2025 (GLOB...

David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
 PRESS RELEASE

Apellis Pharmaceuticals to Participate in Upcoming Investor Conference...

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Citi’s 2025 Global Healthcare Conference Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET Evercore 8th Annual Healthcare Conference  Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section...

 PRESS RELEASE

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan inj...

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injection), the leading treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The results demonstrate that both every-other-month and monthly SYFOVRE delayed GA lesion growth by ap...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch